Cellebrite DI .(CLBT)
搜索文档
VNT vs. CLBT: Which Stock Is the Better Value Option?
Zacks Investment Research· 2024-03-21 00:46
Investors with an interest in Technology Services stocks have likely encountered both Vontier Corporation (VNT) and Cellebrite DI Ltd. (CLBT) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strategy ...
Cellebrite Revolutionizes Data Collection with Ground-breaking SaaS Solution, Integral Part of Company's Case-to-Closure Platform
Newsfilter· 2024-03-14 21:00
TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (NASDAQ:CLBT), a leader in Digital Investigative solutions, today unveils Cellebrite Endpoint Inspector SaaS. This enhanced delivery model of our industry-leading Endpoint Inspector product offers enterprise customers and eDiscovery service providers next-generation digital forensic capabilities that enable the streamlined collection and analysis of data from diverse remote devices, all within a unified, consen ...
Cellebrite DI Ltd. (CLBT) is a Great Momentum Stock: Should You Buy?
Zacks Investment Research· 2024-03-08 02:01
Momentum投资 - Momentum投资是跟随股票近期趋势的理念,可以是向任何方向[1] Zacks Momentum Style Score - Zacks Momentum Style Score是帮助我们解决哪些是最好和最差的指标的问题[2] Cellebrite DI Ltd. (CLBT) - Cellebrite DI Ltd. (CLBT)目前具有A级的Momentum Style Score[3] 股票表现 - Zacks Rank 1 (Strong Buy)和2 (Buy)以及A或B级的Style Scores的股票在接下来的一个月内表现优于市场[4]
Cellebrite Launches FedRAMP Authorization Process to Provide Federal Customers with Enhanced Cloud Security
Newsfilter· 2024-03-07 21:30
Cellebrite宣布启动FedRAMP®过程 - Cellebrite宣布启动授权其软件即服务产品的FedRAMP®过程,以支持联邦客户使用公司的SaaS解决方案[1] - Cellebrite选择了网络安全服务公司Coalfire来支持完成这一过程,计划在接下来的十二个月内完成[2] - Cellebrite与Coalfire的合作将进一步提升公司的安全实践水平,确保其SaaS解决方案符合最高的安全和数据合规标准[3]
Haim Shani Concludes Tenure at Cellebrite as Company Enters Next Growth Phase
Newsfilter· 2024-03-06 20:00
公司动态 - Cellebrite DI Ltd.宣布Haim Shani辞去公司董事职务[1] - Haim Shani离职后,公司CEO Yossi Carmil对其贡献表示感谢,并表示公司将继续前进[2] 公司使命 - Cellebrite致力于成为全球数字调查解决方案的领导者,专注于满足全球客户的需求[3] - 公司使命是通过数字调查解决方案保护和拯救生命,加速司法进程,并在全球社区中保护隐私[4]
Are Business Services Stocks Lagging Cellebrite DI Ltd. (CLBT) This Year?
Zacks Investment Research· 2024-02-26 23:41
公司背景 - Cellebrite DI Ltd. (CLBT) 是 Business Services 领域中的一家公司[1] 行业排名 - CLBT 目前在 Zacks Sector Rank 中排名第7[2] 财务状况 - CLBT 的 Zacks Rank 为 2 (Buy),全年盈利预期上升了22.1%[3] - CLBT 今年迄今为止的回报率为35.2%,高于 Business Services 领域的平均水平[4]
Surging Earnings Estimates Signal Upside for Cellebrite DI Ltd. (CLBT) Stock
Zacks Investment Research· 2024-02-21 02:21
Cellebrite DI Ltd. (CLBT) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock ...
Cellebrite DI Ltd. (CLBT) Is Up 20.78% in One Week: What You Should Know
Zacks Investment Research· 2024-02-20 02:00
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock char ...
Cellebrite DI .(CLBT) - 2023 Q4 - Earnings Call Transcript
2024-02-16 01:01
财务数据和关键指标变化 - 公司2023年第四季度收入为9300万美元,同比增长26%,主要由于订阅收入增长26% [17][55] - 2023年全年收入为3.251亿美元,同比增长20%,其中订阅收入增长30% [56] - 2023年末ARR为3.157亿美元,同比增长27% [57] - 2023年第四季度毛利率为84.5%,同比提升400个基点 [59] - 2023年全年调整EBITDA为6190万美元,占收入19%,同比大幅提升 [62] 各条业务线数据和关键指标变化 - 数字取证业务(Inseyets)持续保持强劲增长,客户升级采用Inseyets的案例显示ARR增长超过65% [24][39][40] - 调查分析业务(Pathfinder)在2023年第四季度创下交易记录,全年约有200个客户使用该解决方案 [29][41] - 证据管理业务(Guardian)正在获得越来越多客户的采用,有助于提高数字取证和调查部门之间的协作效率 [27][28][46] 各个市场数据和关键指标变化 - 美洲市场是公司最大的地理区域,2023年ARR占比53%,同比增长30% [57] - EMEA市场2023年ARR占比36%,同比增长23% [57] - 亚太市场2023年ARR占比11%,同比增长29% [57] 公司战略和发展方向及行业竞争 - 公司正在持续加大对云计算、自动化和人工智能等技术的投入,以提升C2C平台的价值 [30][31][32][33][34] - 公司计划在2024年实现FedRAMP认证,预计将带来美国联邦政府市场的进一步拓展 [123][124][125][126] - 公司正在加强客户中心的销售和客户成功团队,以更好地满足客户需求 [36][61] - 行业内其他竞争对手也在采取提价等措施,公司通过差异化的Inseyets解决方案来提升价值主张 [118][119] 管理层对经营环境和未来前景的评论 - 公司所处的数字取证和调查分析市场整体保持健康增长,客户需求持续旺盛 [19][20] - 公司有望凭借Inseyets、Pathfinder和Guardian等核心解决方案,在未来3年内实现业务规模翻番 [49] - 公司预计2024年ARR增长20%-27%,收入增长14%-18%,调整EBITDA率19%-21% [68][69][70][71][73] 问答环节重要的提问和回答 问题1 **Brad Zelnick 提问** Inseyets的定价策略和对未来增长的影响 [78][79][80] **Yossi Carmil 回答** Inseyets提供更高价值,定价可提高20%-25%,预计未来3年内可覆盖大部分现有客户安装基础 [81][82][83][84][85] 问题2 **Tomer Zilberman 提问** Pathfinder和Guardian业务的收入占比情况 [100][101][102][103] **Yossi Carmil 和 Dana Gerner 回答** Pathfinder和Guardian业务2023年占总收入约10%,未来有望加快增长 [101][102][103][104][105][106][107] 问题3 **Jeff Van Rhee 提问** 公司在从数字取证向调查分析业务拓展方面的进展如何 [109][110][111][112] **Yossi Carmil 回答** 数字取证业务仍是公司主要增长引擎,调查分析业务作为新的增长引擎正在加大投入和专注 [110][111]
Cellebrite DI .(CLBT) - 2023 Q4 - Earnings Call Presentation
2024-02-15 22:27
业绩总结 - 公司2023年第四季度营收达到93,013百万美元,同比增长19%[6] - 公司2023年第四季度毛利为78,097百万美元,毛利率为84.0%[6] - 公司2023年第四季度经营利润为14,999百万美元,经营利润率为16.1%[6] - 公司调整后的EBITDA为22,726百万美元,调整后的EBITDA利润率为24.4%[6] - 公司2023年第四季度净亏损为14,647百万美元[9] - 公司调整后的净收入为21,999百万美元,调整后的基本每股收益为0.12美元[9] - 公司调整后的EBITDA为22,726百万美元[10]